In our forthcoming webinar series we will call on leading experts to share their insights with the audience on some of these questions.
In the first webinar, we will be joined by Dr Casey Quinn, who works with a team at MIT exploring cell and gene therapy financing models. We will discuss what we have learned from ASH, the US experience with CAR-T reimbursement, and the implications for the market access of cell and gene therapies.
In the second webinar, Professor Stephen Palmer from the University of York will join us to discuss his recent work on the assessment of regenerative medicines and cell therapy, and the UK and EU payer perspective on the potential value of these therapies.
These webinars will provide a perspective that spans the clinical and payer landscapes, considers which countries are leading the way in financing cell and gene therapies, and how their approaches can be adopted elsewhere, as well as the implications for the clinical pipeline as the growing number of reimbursed cell and gene therapies strains national budgets.